All In Biotech

Drug Trial Radar · NCT04991935

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

A Phase 3, Multicenter, Multinational, Open-Label Extension Study to Evaluate the Long-Term Safety of CC-93538 in Adult and Adolescent Subjects With Eosinophilic Esophagitis

Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

367

Actual

Start

Aug 9, 2022

Primary completion

Aug 14, 2025

Study completion Aug 14, 2025

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will enroll participants who participated in the CC-93538-EE-001 or CC-93538-DDI-001 studies.

Conditions

  • Eosinophilic Esophagitis

Interventions

  • CC-93538Drug

    CC-93538

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAE)Time frame: From first dose until study completion, early discontinuation, or loss of follow up, whichever occurs first (Up to approximately 36 months)
  2. Number of Participants With Clinically Significant Maximum Post Baseline Shifts in Laboratory ParametersTime frame: From first dose until study completion, early discontinuation, or loss of follow up, whichever occurs first (Up to approximately 36 months)
  3. Number of Participants With Clinically Meaningful Mean Changes in Vital Signs and Physical ParametersTime frame: From first dose until study completion, early discontinuation, or loss of follow up, whichever occurs first (Up to approximately 36 months)

Locations

167 sites in 15 countries. Site status is shown where the registry gives one.

  • Local Institution - 144

    Birmingham, Alabama

  • Local Institution - 082

    Phoenix, Arizona

  • Local Institution - 147

    Phoenix, Arizona

  • Local Institution - 041

    Scottsdale, Arizona

  • Local Institution - 029

    Tucson, Arizona

  • Local Institution - 165

    North Little Rock, Arkansas

  • Local Institution - 075

    Lancaster, California

  • Local Institution - 047

    Los Angeles, California

  • Local Institution - 160

    San Diego, California

  • Local Institution - 068

    Aurora, Colorado

  • Local Institution - 067

    Colorado Springs, Colorado

  • Local Institution - 128

    Wheat Ridge, Colorado

  • Local Institution - 101

    Bristol, Connecticut

  • Local Institution - 076

    Farmington, Connecticut

  • Local Institution - 156

    Hamden, Connecticut

  • Local Institution - 099

    Clearwater, Florida

  • Local Institution - 036

    Inverness, Florida

  • Local Institution - 042

    Jacksonville, Florida

  • Local Institution - 138

    Miami, Florida

  • Local Institution - 146

    Orlando, Florida

  • Local Institution - 169

    Pinellas Park, Florida

  • Local Institution - 168

    Plantation, Florida

  • Local Institution - 037

    Port Orange, Florida

  • Local Institution - 171

    Atlanta, Georgia

  • Local Institution - 054

    Atlanta, Georgia

  • Local Institution - 117

    Macon, Georgia

  • Local Institution - 024

    Idaho Falls, Idaho

  • Local Institution - 039

    Chicago, Illinois

  • Local Institution - 167

    Gurnee, Illinois

  • Local Institution - 127

    Clive, Iowa

  • Local Institution - 094

    Iowa City, Iowa

  • Local Institution - 035

    Kansas City, Kansas

  • Local Institution - 046

    Florence, Kentucky

  • Local Institution - 003

    Baton Rouge, Louisiana

  • Local Institution - 020

    Metairie, Louisiana

  • Local Institution - 044

    Metairie, Louisiana

  • Local Institution - 164

    Columbia, Maryland

  • Local Institution - 070

    Glen Burnie, Maryland

  • Local Institution - 012

    Hagerstown, Maryland

  • Local Institution - 053

    Boston, Massachusetts

Showing 40 of 167 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.